Table S1: Selected direct POCT (antigen/RNA) - WHO TPP Criteria

Manue <t< th=""><th>Country URL URL Intended Use Confirm Target Population / patient Target Population / patient Target use setting Collifie tech win tech tech win tech tech tech tech tech tech tech tech</th><th>Acceptable</th><th>Desirable -2 community wide transmission or -closed community and transmission or -closed community and the light hist transmission of the light hist transmission of the light history of R community hash works (closen has R community hash works) and the action of a program of trained by works (cluster, community hash works) SAMS CoVD and bianster specific fractional and subactory of sources of symptomy (current rectain) - 10⁴ genomic copies/ml detects all SAMS CoVD avies tasing the your common diseases with alling symptoms</th><th>Card Abbot Harc//of-Mass.exen/on Whot Speed/sectors and sector What Subert Indial Qualitative detection of SARS- cov2-angein plastent care setting: POCT meldiduals speeced of COVID-19 within 7 days of sympton onset without and sector and sector patient care setting: CLIA certified tabs SARS-CoV-2 nucleoscipiid protein (and SARS-CoV) 22.5 TODA/web 11225 TODA/web</th><th>Sofu 2 PutsARS Antigen Pia Quidel Corporation USA USA USA USA USA USA USA USA USA USA</th><th>Lumin2b SARS-CoV2 Ag Test LumiraDo LumiraDo HappyTowns Instances Conference Instructional Conference Instructional Conference Instructional Conference COVID-19 (2014) COVID-19 (2014) COVID-1</th><th>COVID-19 Home Test Ellume Australia https://www.ellumehalth.com geallastine detection of SARS- CAV-2 amiliantine detection of SARS- CAV-2 amiliantine detection of SARS- COVID-19 non-prescription home use SARS-COV-2 & SARS-COV</th><th>MobileDetect Bio BCC19 Test (RT-LAMP) DetectsChem Inc. USA http://mobiledictilia.com/ qualifative detection of SARS- CV-2 RNA individual suspected of COVID- 19</th><th>AQ:TOP Plus COVID-39 Repial Test (RTLAMP) SEASUN BIOMATERIALS, Inc. Korea publication of Covid- publication of Covid- qualitative detection of SARS- CoV-2 RNA individual suspected of COVID- 19 certified laboratories</th><th>SARS-CoV-2 Detect Test (RT-LAMP) Mammoth Bioclences, Inc. USA https://mammoth.Bioclovid/ qualitative detection of SARS- coV-2 RNA individual suspected of COVID- 19</th><th>Bioceany Diagnostic kit - COVID-19 Ag test - Shenzhen Bioceasy Biotechnology Co.,14d. http://en.bioesay.com/7p-1038 </th><th>Sofia 2 SARS Antigen FIA Quidel Corporation USA USA USA vip/dm2 - 1 Net samples fail arg/cr/dm2 - 1 Net samples fail arg/cr/dm2 - Net samples fail arg/cr/dm2 - Net samples fail arg/cr/dm</th><th>Standard Q. Covid-19 Ag RiA SD Biosensor, INC. Kores http://https://standard. 622 G22 G22 post post not specified (patient care</th></t<>	Country URL URL Intended Use Confirm Target Population / patient Target Population / patient Target use setting Collifie tech win tech tech win tech tech tech tech tech tech tech tech	Acceptable	Desirable -2 community wide transmission or -closed community and transmission or -closed community and the light hist transmission of the light hist transmission of the light history of R community hash works (closen has R community hash works) and the action of a program of trained by works (cluster, community hash works) SAMS CoVD and bianster specific fractional and subactory of sources of symptomy (current rectain) - 10 ⁴ genomic copies/ml detects all SAMS CoVD avies tasing the your common diseases with alling symptoms	Card Abbot Harc//of-Mass.exen/on Whot Speed/sectors and sector What Subert Indial Qualitative detection of SARS- cov2-angein plastent care setting: POCT meldiduals speeced of COVID-19 within 7 days of sympton onset without and sector and sector patient care setting: CLIA certified tabs SARS-CoV-2 nucleoscipiid protein (and SARS-CoV) 22.5 TODA/web 11225 TODA/web	Sofu 2 PutsARS Antigen Pia Quidel Corporation USA USA USA USA USA USA USA USA USA USA	Lumin2b SARS-CoV2 Ag Test LumiraDo LumiraDo HappyTowns Instances Conference Instructional Conference Instructional Conference Instructional Conference COVID-19 (2014) COVID-19 (2014) COVID-1	COVID-19 Home Test Ellume Australia https://www.ellumehalth.com geallastine detection of SARS- CAV-2 amiliantine detection of SARS- CAV-2 amiliantine detection of SARS- COVID-19 non-prescription home use SARS-COV-2 & SARS-COV	MobileDetect Bio BCC19 Test (RT-LAMP) DetectsChem Inc. USA http://mobiledictilia.com/ qualifative detection of SARS- CV-2 RNA individual suspected of COVID- 19	AQ:TOP Plus COVID-39 Repial Test (RTLAMP) SEASUN BIOMATERIALS, Inc. Korea publication of Covid- publication of Covid- qualitative detection of SARS- CoV-2 RNA individual suspected of COVID- 19 certified laboratories	SARS-CoV-2 Detect Test (RT-LAMP) Mammoth Bioclences, Inc. USA https://mammoth.Bioclovid/ qualitative detection of SARS- coV-2 RNA individual suspected of COVID- 19	Bioceany Diagnostic kit - COVID-19 Ag test - Shenzhen Bioceasy Biotechnology Co.,14d. http://en.bioesay.com/7p-1038 	Sofia 2 SARS Antigen FIA Quidel Corporation USA USA USA vip/dm2 - 1 Net samples fail arg/cr/dm2 - 1 Net samples fail arg/cr/dm2 - Net samples fail arg/cr/dm2 - Net samples fail arg/cr/dm	Standard Q. Covid-19 Ag RiA SD Biosensor, INC. Kores http://https://standard. 622 G22 G22 post post not specified (patient care
MoreMoreMoreMoreMoreMaryme <t< th=""><th>Country URL URL Intended Use Confirm Target Population / patient Target Population / patient Target use setting Collifie tech win tech tech win tech tech tech tech tech tech tech tech</th><th>in areas with confirmed SARS CoV immed contreases in CARS CoV - 2 and Research of the Cover of the Cover of the disease in the regardrace symptoms or contract of index patients (cover of the contract of index patients (cover of the cover of the cover of the Cover of the cover of the Cover of the cover of the Cover of the Cover of the cover of the Cover of the cover of the Cover of the Cover of the Cover of the cover of the Cover of the Cover of the Cover of the cover of the Cover of the Cover of the Cover of the cover of the Cover of the Cover of the Cover of the Cover of the cover of the Cover o</th><th>2 community wide transmission or desarray wide and high wide these functions and high wide these functions. The other transfer takes functions. The other transfer takes functions. The other transfer former COMPUS patients. I former COMPUS patients. I demonstration and the patients of the demonstration of the community health workers. I SABS-GAV only demonstrate granting for common diseases with threat computer of the community and demonstrate and the community and the community health workers. I SABS-GAV only demonstrate granting for common diseases with threat of the community and the community of the demonstrate and the demonstrate and the demonstrate and the demonstrate and the demonstrate and the demonstrate and the demonstrate and the demonstrate and the de</th><th>Card Abbot Harc//of-Mass.exen/on Whot Speed/sectors and sector What Subert Indial Qualitative detection of SARS- cov2-angein plastent care setting: POCT meldiduals speeced of COVID-19 within 7 days of sympton onset without and sector and sector patient care setting: CLIA certified tabs SARS-CoV-2 nucleoscipiid protein (and SARS-CoV) 22.5 TODA/web 11225 TODA/web</th><th>FA Quidet Corporation USA They/orea data.com/mumosite aparliative detaction of SASS- Gov/2 avtagen spectra of SASS- Gov/2 avtagen spectra of SASS- Gov/2 avtagen spectra of color 34 system 5 sky of sympton on set apartem care setting: CLA certified labs SARS-GOV_2 nucleosapaid protein 113 TODau/ml</th><th>Test Lamitalo 1007 (2014 1007 (2014) 1007 (2014) 100</th><th>Ellume Australia https://www.ellumehauth.com gualitative detection of SASS- CaV-2 antigen; non- prescription home use individuals suspected of COVID-19 non-prescription home use SARS-COV-2 & SARS-COV</th><th>Test (RT-LAMP) DetectaChem Inc. USA https://mabileditection.com/ qualitative detection of SARS- Cor-2 RNA individual suspected of COVID- 19 certified laboratories</th><th>Rapid Test (RT-LANP) SEASUN BIOMATERIALS, Inc. Kees http://www.casautio.com/english/ podusts/kees/ qualitative detection of SARS- CoV-2 RNA individual suspected of COVID- 19 certified laboratories</th><th>(RT-LAMP) Mammoth Bioschenes, Inc. USA https://mammoth.bio/covid/ qualitative detection of SARS- Gor2 RNA individual suspected of COVID- 19</th><th>COVID-19 Ag test Shenchen Biotosay Biotechnology Co., 14. Ohna Intg. / en. bioesay. com/7p=1018 qualitative detection of SARS- CoV-2 in patient care setting; POCT individual suspected of COVID- 19 not specified (patient care</th><th>Quidel Corporation USA USA USA upp://clav.bk.acs.atego.nfa qualitative detection of SARS- CoV-2 in patient care setting: PCCT undividuals suspected of COVID-19 within S days of sympton onset patient care setting: CLIA</th><th>FIA SD Biosensor, INC. Korea http://tdiosensor.com/wf/product/7 672 qualitative detection of SARS- GOV-2 in patient care setting: POCT post not specified (patient care</th></t<>	Country URL URL Intended Use Confirm Target Population / patient Target Population / patient Target use setting Collifie tech win tech tech win tech tech tech tech tech tech tech tech	in areas with confirmed SARS CoV immed contreases in CARS CoV - 2 and Research of the Cover of the Cover of the disease in the regardrace symptoms or contract of index patients (cover of the contract of index patients (cover of the cover of the cover of the Cover of the cover of the Cover of the cover of the Cover of the Cover of the cover of the Cover of the cover of the Cover of the Cover of the Cover of the cover of the Cover of the Cover of the Cover of the cover of the Cover of the Cover of the Cover of the cover of the Cover of the Cover of the Cover of the Cover of the cover of the Cover o	2 community wide transmission or desarray wide and high wide these functions and high wide these functions. The other transfer takes functions. The other transfer takes functions. The other transfer former COMPUS patients. I former COMPUS patients. I demonstration and the patients of the demonstration of the community health workers. I SABS-GAV only demonstrate granting for common diseases with threat computer of the community and demonstrate and the community and the community health workers. I SABS-GAV only demonstrate granting for common diseases with threat of the community and the community of the demonstrate and the demonstrate and the demonstrate and the demonstrate and the demonstrate and the demonstrate and the demonstrate and the demonstrate and the de	Card Abbot Harc//of-Mass.exen/on Whot Speed/sectors and sector What Subert Indial Qualitative detection of SARS- cov2-angein plastent care setting: POCT meldiduals speeced of COVID-19 within 7 days of sympton onset without and sector and sector patient care setting: CLIA certified tabs SARS-CoV-2 nucleoscipiid protein (and SARS-CoV) 22.5 TODA/web 11225 TODA/web	FA Quidet Corporation USA They/orea data.com/mumosite aparliative detaction of SASS- Gov/2 avtagen spectra of SASS- Gov/2 avtagen spectra of SASS- Gov/2 avtagen spectra of color 34 system 5 sky of sympton on set apartem care setting: CLA certified labs SARS-GOV_2 nucleosapaid protein 113 TODau/ml	Test Lamitalo 1007 (2014 1007 (2014) 1007 (2014) 100	Ellume Australia https://www.ellumehauth.com gualitative detection of SASS- CaV-2 antigen; non- prescription home use individuals suspected of COVID-19 non-prescription home use SARS-COV-2 & SARS-COV	Test (RT-LAMP) DetectaChem Inc. USA https://mabileditection.com/ qualitative detection of SARS- Cor-2 RNA individual suspected of COVID- 19 certified laboratories	Rapid Test (RT-LANP) SEASUN BIOMATERIALS, Inc. Kees http://www.casautio.com/english/ podusts/kees/ qualitative detection of SARS- CoV-2 RNA individual suspected of COVID- 19 certified laboratories	(RT-LAMP) Mammoth Bioschenes, Inc. USA https://mammoth.bio/covid/ qualitative detection of SARS- Gor2 RNA individual suspected of COVID- 19	COVID-19 Ag test Shenchen Biotosay Biotechnology Co., 14. Ohna Intg. / en. bioesay. com/7p=1018 qualitative detection of SARS- CoV-2 in patient care setting; POCT individual suspected of COVID- 19 not specified (patient care	Quidel Corporation USA USA USA upp://clav.bk.acs.atego.nfa qualitative detection of SARS- CoV-2 in patient care setting: PCCT undividuals suspected of COVID-19 within S days of sympton onset patient care setting: CLIA	FIA SD Biosensor, INC. Korea http://tdiosensor.com/wf/product/7 672 qualitative detection of SARS- GOV-2 in patient care setting: POCT post not specified (patient care
Name	Country URL URL Intended Use Confirm Target Population / patient Target Population / patient Target use setting Collifie tech win tech tech win tech tech tech tech tech tech tech tech	Immed outbreaks in closed or semi- control of the set o	-cload comunities and in high risk cloader. Comunities and in high risk cloaders. Cloaders and cloaders and cloaders in continued or polyces (cloan charge) its community cloan cloaders (cloaders) its community cloaders oversion. Same as a scapabilis bat can be self- mented CVD-15 gates (cloaders) its community health workers) Same (cloaders) and cloaders (cloaders) trained ally workers (cloaders) for scale and scales of smptoms/current interiority of symptoms/current interiority of scales cloaders (cloaders) and cloader cloaders cloaders with cloader humans CVD or common diseases with similar symptoms.	Abbott USA They://am.abbot.com/on- ub/mergage/company/abboth w/ act abbott.com/on- ub/mergage/company/abboth apalitative detection of SARS- detting: PBCT area they applied on the antibility of the second of COVID-19 within 7 days of apatient care setting: CLIA certified labs SARS-CoV-2 nucleocapsid protein (and SARS-CoV) 22.5 TOLDs/swab 11225 TOLS/ymb) no or cross-reactivity in a panel	Cadel Corporation USA USA USA USA USA USA USA USA USA USA	LumiraDe UKP USA URV, USA URV, USA URV, USA URV, USA USA USA USA USA USA USA USA	Australia https://www.ellumehealth.com qualitative detection of SARS- CoV-2 artigen, non- prescription home use individuals suspected of COVID-19 non-prescription home use SARS-CoV-2 & SARS-CoV	Detects/Dem Inc. USA https://mobilestectlis.com/ qualitative detection of SARS- CoV-2 RNA individual suspected of COVID- 19 certified laboratories	SEASUN BIOMATERIALS, Inc. Korea http://www.sasorbito.com/engish/ productsk.itemi qualitative detection of SARS- CoV-2 RNA individual suspected of COVID- 19 certified laboratories	Mammoth Biosciences, Inc. USA https://mammoth.bio/covid/ qualitative detection of SARS- CoV-2 RNA individual suspected of COVID- 19	Shenzhen Bioessy Biotechnology Co.Ltd. Unina http://en.bioessy.com/7p-1038 qualitative detection of SARS- COV-3 in patient care setting; POCT individual suspected of COVID- 19 not specified (patient care	USA https://www.subit.com/immunosis ary/club 2 ho-sars-attgen for qualitative detection of SARS- GOV 2 in patient care setting; POCT individuals suspected of COVID-19 within 5 days of sympton onset patient care setting; CLIA	SD Biosensor, INC. Kores http://https://sourcestor.com/ar/product/7 022 com/ar in patient care setting; POCT post not specified (patient care
Image <br< th=""><th>Country URL URL Intended Use Confirm Target Population / patient Target Population / patient Target use setting Collifie tech win tech tech win tech tech tech tech tech tech tech tech</th><th>Immed outbreaks in closed or semi- control of the set o</th><th>-cload comunities and in high risk cloader. Comunities and in high risk cloaders. Cloaders and cloaders and cloaders in continued or polyces (cloan charge) its community cloan cloaders (cloaders) its community cloaders oversion. Same as a scapabilis bat can be self- mented CVD-15 gates (cloaders) its community health workers) Same (cloaders) and cloaders (cloaders) trained ally workers (cloaders) for scale and scales of smptoms/current interiority of symptoms/current interiority of scales cloaders (cloaders) and cloader cloaders cloaders with cloader humans CVD or common diseases with similar symptoms.</th><th>USA Theo:/dom.stanst.envyton. wt/norospag/comousive/feasoof wt/asticates/intigeff qualitative detection of SARS- 602-2 angien in patient care setting: POCT individuals supported patient care setting; CLIA patient care setting; CLIA patient care setting; CLIA certified tabs SARS-CoV-2 nucleosciptid protein (and SARS-CoV) 22.5 TOLDou/weak 11.122 TOLDOU/mol)</th><th>USA https://www.add.com/immuosas apultable available and another apultable available and another individuals suspected of Voim 35 with a Say of sympton omat patient care setting; PCU- DVOID-34 within 5 say of sympton context patient care setting; CLIA certified labs SARS-GOV 3 nucleocapaid protein 113 TCDg/ml</th><th>UK / USA Thep://www.lineak.com/uc- buchologic/alignedia.com/uc- buchologic/alignedia.com/uc- ausilitative detection of SARS- Gold 2 angles in patient care setting. POLT imdividual suspected of QUVD139 within 12 days of sympton onset. Dattert care setting: CUA certified labs SARS-GoV-2 nucleocapsid protein</th><th>Australia https://www.ellumehealth.com qualitative detection of SARS- CoV-2 artigen, non- prescription home use individuals suspected of COVID-19 non-prescription home use SARS-CoV-2 & SARS-CoV</th><th>USA https://mobiledetaction.com/ qualitative detection of SARS- CaV-2 RNA individual suspected of COVID- 19 certified laboratories</th><th>Korea http://www.usasorbio.com/engish/ productsk.tml qualitative detection of SARS- CoV-2 RNA individual suspected of COVID- 19</th><th>USA https://manmath.bio/covid/ qualitative detection of SARS- CoV-2 RNA individual suspected of COVID- 19</th><th>Biotechnology Co., Ltd. China http://en.bioasay.com/7p-1038 div/2en.bioasay.com/7p-1038 Co/2-3 in patient care setting; POCT individual suspected of COVID- 19 not specified (patient care</th><th>USA https://www.subit.com/immunosis ary/club 2 ho-sars-attgen for qualitative detection of SARS- GOV 2 in patient care setting; POCT individuals suspected of COVID-19 within 5 days of sympton onset patient care setting; CLIA</th><th>Korea http://discense.com/w/product/7 672 qualitative detection of SARS- CoV-2 in patient care setting; POCT post not specified (patient care</th></br<>	Country URL URL Intended Use Confirm Target Population / patient Target Population / patient Target use setting Collifie tech win tech tech win tech tech tech tech tech tech tech tech	Immed outbreaks in closed or semi- control of the set o	-cload comunities and in high risk cloader. Comunities and in high risk cloaders. Cloaders and cloaders and cloaders in continued or polyces (cloan charge) its community cloan cloaders (cloaders) its community cloaders oversion. Same as a scapabilis bat can be self- mented CVD-15 gates (cloaders) its community health workers) Same (cloaders) and cloaders (cloaders) trained ally workers (cloaders) for scale and scales of smptoms/current interiority of symptoms/current interiority of scales cloaders (cloaders) and cloader cloaders cloaders with cloader humans CVD or common diseases with similar symptoms.	USA Theo:/dom.stanst.envyton. wt/norospag/comousive/feasoof wt/asticates/intigeff qualitative detection of SARS- 602-2 angien in patient care setting: POCT individuals supported patient care setting; CLIA patient care setting; CLIA patient care setting; CLIA certified tabs SARS-CoV-2 nucleosciptid protein (and SARS-CoV) 22.5 TOLDou/weak 11.122 TOLDOU/mol)	USA https://www.add.com/immuosas apultable available and another apultable available and another individuals suspected of Voim 35 with a Say of sympton omat patient care setting; PCU- DVOID-34 within 5 say of sympton context patient care setting; CLIA certified labs SARS-GOV 3 nucleocapaid protein 113 TCDg/ml	UK / USA Thep://www.lineak.com/uc- buchologic/alignedia.com/uc- buchologic/alignedia.com/uc- ausilitative detection of SARS- Gold 2 angles in patient care setting. POLT imdividual suspected of QUVD139 within 12 days of sympton onset. Dattert care setting: CUA certified labs SARS-GoV-2 nucleocapsid protein	Australia https://www.ellumehealth.com qualitative detection of SARS- CoV-2 artigen, non- prescription home use individuals suspected of COVID-19 non-prescription home use SARS-CoV-2 & SARS-CoV	USA https://mobiledetaction.com/ qualitative detection of SARS- CaV-2 RNA individual suspected of COVID- 19 certified laboratories	Korea http://www.usasorbio.com/engish/ productsk.tml qualitative detection of SARS- CoV-2 RNA individual suspected of COVID- 19	USA https://manmath.bio/covid/ qualitative detection of SARS- CoV-2 RNA individual suspected of COVID- 19	Biotechnology Co., Ltd. China http://en.bioasay.com/7p-1038 div/2en.bioasay.com/7p-1038 Co/2-3 in patient care setting; POCT individual suspected of COVID- 19 not specified (patient care	USA https://www.subit.com/immunosis ary/club 2 ho-sars-attgen for qualitative detection of SARS- GOV 2 in patient care setting; POCT individuals suspected of COVID-19 within 5 days of sympton onset patient care setting; CLIA	Korea http://discense.com/w/product/7 672 qualitative detection of SARS- CoV-2 in patient care setting; POCT post not specified (patient care
network image rem rem <td< td=""><td>URL 3) in a contrast of the second se</td><td>Immed outbreaks in closed or semi- control of the set o</td><td>-cload comunities and in high risk cloader. Comunities and in high risk cloaders. Cloaders and cloaders and cloaders in continued or polyces (cloan charge) its community cloan cloaders (cloaders) its community cloaders oversion. Same as a scapabilis bat can be self- mented CVD-15 gates (cloaders) its community health workers) Same (cloaders) and cloaders (cloaders) trained ally workers (cloaders) for scale and scales of smptoms/current interiority of symptoms/current interiority of scales cloaders (cloaders) and cloader cloaders cloaders with cloader humans CVD or common diseases with similar symptoms.</td><td>HIGD: 7/40m, 32804 Conv/ W = 20 Shart Train 201 W = 201 W</td><td>They/Lorea Justic Son/Immonian with/lab 2 biases anigment againstative detection of SABS- DV2 a subject in patient care tables the subject of SABS- DV2 a subject of SABS- DV2 a subject of SABS- SABS GV2 A subject of SABS- COUND-3 with the SABS of SABS of SABS SABS GV2 A subject of SABS of SABS of SABS SABS GV2 A subject of SABS of SABS of SABS SABS GV2 A subject of SABS of SABS of SABS SABS GV2 A subject of SABS of SAB</td><td>http://www.luminat.com/u- internationality/internationality/ without we dologicality in control of SARS- CoV-2 antigen in patient care setting: POCT undividuals suspected of COVID-10 within 12 days of sympton oncet patient care setting: CLIA certified labs SARS-CoV-2 nucleocapsid protein</td><td>https://www.ellumeheulth.com Gallathee detection of SARS- CoV-2 antigen; non- prescription home use individuals suspected of COVID-19 non-prescription home use SARS-CoV-2 & SARS-CoV</td><td>https://mdakustection.com/ qualitative detection of SARS- CoV-2 RNA individual suspected of COVID- 19</td><td>http://www.seasorbia.com/ungita/ productier.text qualitative detection of SARS- CoV-2 RNA individual suspected of COVID- 19 certified laboratories</td><td>http://manmoth.bio/covid/ qualitative detection of SARS- CoV-2 RNA individual suspected of COVID- 19</td><td>http://en.bioasay.com/?p-1038 qualitative detection of SARS- CoV-2 in patient care setting; POCT individual suspected of COVID- 19 not specified (patient care</td><td>https://www.guidu.com/immunouss aryu/crinia-2ns-uary-angen.fu qualitative detection of SARS- CoV-2 in patient care setting; POCT individuals suspected of COVID-19 within 5 days of sympton onset patient care setting; CLIA</td><td>http://sdbiosensor.com/we/product/7 672 qualitative detection of SARS- CoV-2 in patient care setting; POCT post not specified (patient care</td></td<>	URL 3) in a contrast of the second se	Immed outbreaks in closed or semi- control of the set o	-cload comunities and in high risk cloader. Comunities and in high risk cloaders. Cloaders and cloaders and cloaders in continued or polyces (cloan charge) its community cloan cloaders (cloaders) its community cloaders oversion. Same as a scapabilis bat can be self- mented CVD-15 gates (cloaders) its community health workers) Same (cloaders) and cloaders (cloaders) trained ally workers (cloaders) for scale and scales of smptoms/current interiority of symptoms/current interiority of scales cloaders (cloaders) and cloader cloaders cloaders with cloader humans CVD or common diseases with similar symptoms.	HIGD: 7/40m, 32804 Conv/ W = 20 Shart Train 201 W = 201 W	They/Lorea Justic Son/Immonian with/lab 2 biases anigment againstative detection of SABS- DV2 a subject in patient care tables the subject of SABS- DV2 a subject of SABS- DV2 a subject of SABS- SABS GV2 A subject of SABS- COUND-3 with the SABS of SABS of SABS SABS GV2 A subject of SABS of SABS of SABS SABS GV2 A subject of SABS of SABS of SABS SABS GV2 A subject of SABS of SABS of SABS SABS GV2 A subject of SABS of SAB	http://www.luminat.com/u- internationality/internationality/ without we dologicality in control of SARS- CoV-2 antigen in patient care setting: POCT undividuals suspected of COVID-10 within 12 days of sympton oncet patient care setting: CLIA certified labs SARS-CoV-2 nucleocapsid protein	https://www.ellumeheulth.com Gallathee detection of SARS- CoV-2 antigen; non- prescription home use individuals suspected of COVID-19 non-prescription home use SARS-CoV-2 & SARS-CoV	https://mdakustection.com/ qualitative detection of SARS- CoV-2 RNA individual suspected of COVID- 19	http://www.seasorbia.com/ungita/ productier.text qualitative detection of SARS- CoV-2 RNA individual suspected of COVID- 19 certified laboratories	http://manmoth.bio/covid/ qualitative detection of SARS- CoV-2 RNA individual suspected of COVID- 19	http://en.bioasay.com/?p-1038 qualitative detection of SARS- CoV-2 in patient care setting; POCT individual suspected of COVID- 19 not specified (patient care	https://www.guidu.com/immunouss aryu/crinia-2ns-uary-angen.fu qualitative detection of SARS- CoV-2 in patient care setting; POCT individuals suspected of COVID-19 within 5 days of sympton onset patient care setting; CLIA	http://sdbiosensor.com/we/product/7 672 qualitative detection of SARS- CoV-2 in patient care setting; POCT post not specified (patient care
Image: second	1) In a 10 intended Use 10 intend	Immed outbreaks in closed or semi- control of the set o	-cload comunities and in high risk cloader. Comunities and in high risk cloaders. Cloaders and cloaders and cloaders in continued or polyces (cloan charge) its community cloan cloaders (cloaders) its community cloaders oversion. Same as a scapabilis bat can be self- mented CVD-15 gates (cloaders) its community health workers) Same (cloaders) and cloaders (cloaders) trained ally workers (cloaders) for scale and scales of smptoms/current interiority of symptoms/current interiority of scales cloaders (cloaders) and cloader cloaders cloaders with cloader humans CVD or common diseases with similar symptoms.	nolifishe detection of SARS- or-X anagen in patient care setting: ROCT individuals suspected of COUDLS 19 within A days of sympton creat: patient care setting: CLA certified labs SARS-CAV-3 nucleocopyid protein (and SARS-CAV) 22.5 TOLOJ/web (1125 TOLOJ/msh)	ayluha 23 Ausas sitepa 48 Semitina Peterlan (Sangaran Sangara) Gui 24 August 24 August 24 August 24 Individuals suspected of COVID-19 August 24 August 24 Individuals suspected of COVID-19 August 24 August 24 Pattert care setting: CLIA certified labs SASE CoVID-10 August 24 SASE COVID-10 August	uchookgy/angen tour qualitative detection of SABS- CoV-2 antigen in patient care setting: POCT individuals supported of COVID-19 within 12 days of sympton onset patient care setting: CLIA certified labs SARS-CoV-2 nucleocapsid protein	qualitative detection of SARS- CoV-2 antiger, non- prescription home use individuals suspected of COVID-19 non-prescription home use SARS-CoV-2 & SARS-CoV	qualifative detection of SARS- CaV-2 RNA individual suspected of COVID- 19 certified laboratories	poducts Real qualitative detection of SARS- CaV-2 RNA individual suspected of COVID- 19 certified laboratories	qualitative detection of SARS- CoV-2 RNA individual suspected of COVID- 19	qualitative detection of SARS- CoV-2 in patient care setting; POCT individual suspected of COVID- 19 not specified (patient care	ayd/sdfa-2-fb-sart-antgen-fa qualitative detection of SARS- CaV-2 in patient care setting; POCT individuals suspected of COVID-19 within 5 days of sympton onset patient care setting; CLIA	672 qualitative detection of SARS- CoV-2 in patient care setting; POCT post not specified (patient care
Image: Participant set of the set of	Intended Use Confirm group; and patient patient Target Population / patient analons apatient Target use setting dickide i facilities Target use setting facilities apatient Target molecule SARS-CO sections Analytical sensitivity / LOD Lo ⁴ get with sim and dose Col4 Joint Sensitivity (or PPA) a SON Seccificity (or VPA) Sensitivity (or PPA) a SON Seccificity (or use) Type of analysis qualitating use of the second seco	Immed outbreaks in closed or semi- control of the set o	-cload comunities and in high risk cloader. Comunities and in high risk cloaders. Cloaders and cloaders and cloaders in continued or polyces (cloan charge) its community cloan cloaders (cloaders) its community cloaders oversion. Same as a scapabilis bat can be self- mented CVD-15 gates (cloaders) its community health workers) Same (cloaders) and cloaders (cloaders) trained ally workers (cloaders) for scale and scales of smptoms/current interiority of symptoms/current interiority of scales cloaders (cloaders) and cloader cloaders cloaders with cloader humans CVD or common diseases with similar symptoms.	nolifishe detection of SARS- or-X anagen in patient care setting: ROCT individuals suspected of COUDLS 19 within A days of sympton creat: patient care setting: CLA certified labs SARS-CAV-3 nucleocopyid protein (and SARS-CAV) 22.5 TOLOJ/web (1125 TOLOJ/msh)	CoV-2 artigen in patient care setting: POCT individuals suspected of COVID-19 within 5 days of patient care setting: CLIA certified labs SARS-CoV-2 nucleocapsid protein 113 TCDb ₀ /ml	qualitative detection of SARS- CoV-2 antigen in patient care setting: POCT individuals suspected of COVID-19 within 12 days of sympton onset patient care setting: CLIA certified labs SARS-CoV-2 nucleocapsid protein	CoV-2 antigen; non- prescription home use individuals suspected of COVID-19 non-prescription home use SARS-CoV-2 & SARS-CoV	COV-2 RNA individual suspected of COVID- 19 certified laboratories	COV-2 RNA individual suspected of COVID- 19 certified laboratories	CoV-2 RNA individual suspected of COVID- 19	CoV-2 in patient care setting; POCT individual suspected of COVID- 19 not specified (patient care	CoV-2 in patient care setting; POCT individuals suspected of COVID-19 within 5 days of sympton onset patient care setting; CLIA	CoV-2 in patient care setting; POCT post not specified (patient care
Subscription Subscripiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii	Target Population / patient anomin anomin Target use setting cutside 1 control technic technic technic Target use setting stat-control technic technic Analytical specificity yoo Analytical specificity technic technic Senset-control and does with sim setting and does control control technic Sensitivity (or PPA) 2 80% 2 80% Specificity (or PPA) 2 80% 2 80% Type of analysis qualitatit qualitatity	mia) and ether a known constact with Constant of Inliving in an area of cluster O constact of Index patients (con- stant) and the constant of the constant o	this a confined or probable (DDN-D) (Rommany Transmission, and Gase finimed (DDN-D) spatients) and a scapatible discussion. And a scapatible discussion. And a scapatible discussion. And	COVID-19 within 7 days of sympton onset patient care setting; CLIA certified labs SARS CoV-2 nucleoscapid protein (and SARS CoV) 22.5 T(CID_s/reab (1125 T(CIDS)/m)) no cross-reactivity in a panel	COVID-19 within 5 days of sympton onset patient care setting; CLIA certified labs SARS-CoV-2 nucleocapsid protein 113 TCID ₆₀ /ml	COVID-19 within 12 days of sympton onset patient care setting; CLIA certified labs SARS-CoV-2 nucleocapsid protein	COVID-19 non-prescription home use SARS-CoV-2 & SARS-CoV	19 certified laboratories	19 certified laboratories	19	19 not specified (patient care	COVID-19 within 5 days of sympton onset	
NameN	Target use setting Screening facilities facilities Target molecule SARS-Cr Target molecule Setting Anshytical sensitivity / LOD - u5 are setting Anshytical sensitivity / LOD - u5 are setting Anshytical sensitivity / LOD - u5 are setting Sensitivity (or PPA) 2 87% Sensitivity (or PPA) 2 80% Sensitivity (or PPA) 2 80% Sensitivity (or PPA) 2 80% Sensitivity and analysis Qualifiation	ning points of health care ies by health care works or lab with appropriate training to use st. Corb Joannafer (INA), antigen) Er oracter (Intra weak after of symptoms/current infection genomic cogres/ml to II ABA-Corb 2xind infantion one on corbox seat entitle offer corb bed corbox seat entitle offer corbox seat entitle offer to corbox seat entitle of	administered and/or performed by trained lay workers (volunteer, community health workers) SASS-GX-2 only biomarker specific for acute and subacute (first 2 weeks after onset of symptoms/current infection) - 10 ¹ genomic copies/ml detects all SARS-GX-2 wirds attrains and dose not cross east with other human COV or common diseases with similar symptoms	certified labs SARS-CoV-2 nucleocapsid protein (and SARS-CoV) 22.5 TCIDs/swab (1125 TCID50/ml) no cross-reactivity in a panel	SARS-CoV-2 nucleocapsid protein 113 TCID ₅₀ /ml	certified labs SARS-CoV-2 nucleocapsid protein	SARS-CoV-2 & SARS-CoV			certified laboratories		patient care setting; CLIA certified labs	
Ander Schware	Target molecule specific f Analytical sensitivity / LOD 10 ⁶ ger Analytical sensitivity / LOD 10 ⁶ ger Analytical specificity Human or Main Strain Ger Sensitivity (or PPA) 207% Type of analysis qualitatit	Corb Biomariere (RNA, antigen) (Eror acute (Instrucek after of symptoms/current infection) genomic copies/mil atl SARS-CoV-2 viral strains ose not cross react with other coronaviuses (cereșt SARS- c) or any other common diseases i imiliar symptoms (influenz a, v, malaria, dengue) s s s	for acute and subacter (First 2 weeks after onset of symptoms/current infection) ~ 10 ⁶ genomic copies/ml detects all SARS-CoV-2 virls strains and dose not cross react with other human COV or common diseases with similar symptoms 2 90%	protein (and SARS-CoV) 22.5 TCID ₂₀ /swab (1125 TCID50/ml) no cross-reactivity in a panel	protein 113 TCID _{so} /ml	protein		CARE Cold 2 M and 5 mores					
MAMAM Markadow Markado	detects and does and does human or with superflicity Sensitivity (or PPA) 2 80% Specificity (or PPA) 2 87% qualitati Type of analysis qualitati q	ts all SAR-CoV-2 viral strains ose not cross react with other in coronaviruses (except SARS-) or any other common diseases imiliar symptoms (influenza A, v, malaria, dengue) 5	detects all SARS-CoV-2 virla strains and dose not cross react with other human CoV or common diseases with similar symptoms 2 90%	(1125 TCID50/ml)		32 TCID _{so} /ml		SARS-COV-2 IV and E genes	genes SARS-CoV-2 N genes r		n/a		SARS-CoV-2 nucleocapsid protein
NameParticipant is a space of the space of t	Analytical specificity and dose human or Qr/-3) or with sim § nsitivity (or PPA) \$ 850% § Specificity (or PPA) \$ 257% Type of analysis qualitati qualitati qualitati data dose qualitati data dose data dose qualitati data dose data dos data dos data dos data dose data dose data dos data dose data dos data dos data dos data dos data dos data dos data da data dose data dos data data dos data da data dos data data da da data da data da da da data da data da da da data da data da	ose not cross react with other or oronaviruses (except SARS- i or any other common diseases) or any other common diseases (iniliar symptoms (influenza A, s) V, malaria, dengue) 5 2 2 3 2 2 3 2 3 2 3 2 3 3 3 3 3 3 3 3	and dose not cross react with other human CoV or common diseases with similar symptoms 2 90%	no cross-reactivity in a panel			6310 TCID ₅₀ /ml	75 copies/µl	1 copies/µl	20 copies/µl	n/a	113 TCID50/ml	494.5 TCID50/ml
Sending in the sendence in the sendenc	Specificity (or NPA) 297% Type of analysis	5 2			of high prevalence respiratory	no cross-reactivity in a panel of high prevalence respiratory pathogens	no cross-reactivity in a panel of high prevalence respiratory pathogens	of high prevalence respiratory	of high prevalence respiratory	no cross-reactivity in a panel of high prevalence respiratory pathogens	n/a	of high prevalence respiratory	n/a
ParameterNameterNameterSubscient <th< td=""><td>Type of analysis qualitatin quantitat</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>	Type of analysis qualitatin quantitat												
Mathematical	signal ma		N/A		lateral flow	microfluidic	lateral flow				fluorescent immunochromatographic,	lateral flow	fluorescent immunoassay
Marka	Interpretation (propriet	(proprietary or smart phone) via smartphone app reader with		visual manual read	digital readout	digital readout	digital readout (smartphone)	visual color recognition	digital readout	digital readout		digital readout	digital readout
Indication Indicat	Sample type nasophar	nasopharyngeal, oropharyngeal, nasal anterior nares (swab), saliva/oral swab nasal wash snetum fluid snetum		nasal swab	nasal swab	nasal swab	nasal swab	nasal swab	nasal swab; BAL	nasal swab / wash	nasal swab	nasal swab	nasal swab
Rest of the short we have a field or sensitive of the sensitive of t	compatib	atible with an existing swab	compatible with multiple swab materials (self-collection or no swab	swabs in the kit ONLY	swabs in the kit ONLY	recommended swab (not included)	swabs in the kit ONLY				not provided	swabs in the kit ONLY	swab provided in kit
Image Mathema and anti- Mathema anti- <th< td=""><td>End use profile trained s</td><td></td><td>trained staff or community level (lay</td><td colspan="2">medical professional or trained staff in certified patient care retting</td><td>personnel and individuals trained in point of care</td><td>home use</td><td colspan="2">rained lab personnel trained lab personnel</td><td>trained lab personnel</td><td>trained medical / lab operator</td><td>personnel and individuals trained in point of care</td><td>professional use</td></th<>	End use profile trained s		trained staff or community level (lay	medical professional or trained staff in certified patient care retting		personnel and individuals trained in point of care	home use	rained lab personnel trained lab personnel		trained lab personnel	trained medical / lab operator	personnel and individuals trained in point of care	professional use
Image not intermediation May of the matrix intermediation May of the m	Training needs 0.5 days quick refe	ays with instructions for use and 2 reference guide(s)	2hr with instructions, quick reference guide including smart phone app(s)	N/A (procedure card included)	N/A	N/A	no	Yes	Yes	Yes	n/a	N/A	n/a
Image and state sta		1	0	1	1	1	1	1	1	1	1	1	1
Jack and mathemation Information Mark Mark <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>													
order of participationOperation of participationOper			extraction buffer/diluent										
Image Space Space <th< td=""><td>Need to transfer a precise autofill o volume of sample on sample</td><td></td><td></td><td>no, few drops</td><td>no, few drops</td><td>no, few drops</td><td>no, few drops</td><td>pipette fixed volumes</td><td>pipette fixed volumes</td><td>pipette fixed volumes</td><td>no, few drops</td><td>no, few drops</td><td>no, few drops</td></th<>	Need to transfer a precise autofill o volume of sample on sample			no, few drops	no, few drops	no, few drops	no, few drops	pipette fixed volumes	pipette fixed volumes	pipette fixed volumes	no, few drops	no, few drops	no, few drops
SubscriptionInternational Sector 1, 20 (sector)International Sector 1, 20 (sector)International Sector 2, 20 (5	guided workflows and built-in timers to reduce user errors on timed steps	1	1	1	1	2	2	2	1 (automatic by analyzer)	1	1
Sander Laber de laber de la fine laber de la fine laber de la				15min	15min	12min	15min	30min	30min	45min	10min	15min	30min
Label value		n (10-35oC); 2-4hr (4-8oC);	preserved samples; 3hr (10-40oC);	<1hr room temp	48hr room temperature or 2- 8oC	Shr room temp; 5 days frozen 80oC	n/a	n/a	n/a	n/a	<24hr at 2-80C; or -70oC long- term	48hr room temperature or 2- 8oC	24h room temperature; 2-8oC for 48hr
Index of and operatorGSK insulf serupt subinorGSK insulf serupt subinorGAS operator d_{A} <t< td=""><td></td><td></td><td></td><td><30min</td><td><30min</td><td>n/a</td><td>n/a</td><td>n/a</td><td>n/a</td><td>n/a</td><td>n/a</td><td><30min</td><td>n/a</td></t<>				<30min	<30min	n/a	n/a	n/a	n/a	n/a	n/a	<30min	n/a
Dependence 13-Soc, 75.506, 814 up 1020001 12-Soc, 75.67, 75.64 up 10200001 12-Soc, 75.67, 75.64 up 10200001 Non temperature Non temperature </td <td></td> <td>nvalid results with correct use by</td> <td><0.5% invalid results with correct use</td> <td>n/a</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>n/a</td> <td></td> <td>n/a</td>		nvalid results with correct use by	<0.5% invalid results with correct use	n/a							n/a		n/a
Test us using words words participation absolution statutes build part words part words absolution statutes	operator	tor b oC. 25-80% RH up to 1500m 1		Room temperature							2-35oC: RH 40-90%	* *	room temperature
LetterMatcher <t< td=""><td>10</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>	10												
Specimen Specin Specin Specin Speci				2-30oC; expiration n/a	room temperature, 15-30oC	2-8oC	2-30oC	freeze at -20oC	freeze at -20oC	freeze at -20oC	2-30 oC	room temperature, 15-30oC	room temperture (2-30oC)
introduction Name Name <td>6</td> <td></td> <td>n/a</td>	6												n/a
Safety precasion Instantimize the need for participation recommends Instantification recommends <thinstantication recommends<="" th=""> <thinstantificati< td=""><td></td><td></td><td></td><td>n/a</td><td>n/a</td><td>n/a</td><td>n/a</td><td>n/a</td><td>n/a</td><td>1500 sample in 8hr</td><td>n/a</td><td>n/a</td><td>n/a</td></thinstantificati<></thinstantication>				n/a	n/a	n/a	n/a	n/a	n/a	1500 sample in 8hr	n/a	n/a	n/a
Quality control Mony/ingration; positive and regarine control power and regarind regarind regarine control power and regarind regarine control		ard respiratory sample collection	biosafety requirement are strongly preferred (e.g. with a self-sample collection device with virus										standard respiratory sample precautions
Remote connective gas to far star star und existing and the skilling to regard to far star star und existing and the skilling to regard to an exist one of gas to star star star star star star star star	Quality control flow/mig	migration); positive and negative	control and negative control provided			internal control; pos/neg control	internal control		internal control; pos/neg control		internal control		internal control; pos/neg controls separate
no additional equipment required, but	not requi Remote connectivity capacity tests: if c	tquired for reader independent of evice-based: remote export of a possible of the state of the s	other data capture devices; internal memory to store results even if power cut and with the ability to report to country health information management systems using on onboard unique identifier or other personal data protection safetguard linking the test.	no	n/a	optional	Smartphone compatible	n/s	n/a	n/a	n/3	n/a	n/a
equipment in by participating for analytic applications in a participation of a gial a constraining through in a participation of a gial a constraining through in a participation of a gial a constraining through a constraining th	equipment or solar p	rechargable battery life smartphone applications		no	Sofia / Sofia 2 instrument		Smartphone	MD-Bio Heater (or thermal cycler)	CFX 96 PCR system	CFX 96 PCR system	Yes, fluorescece analyzer	Sofia / Sofia 2 instrument	Standard F Analyzer
Ned for materimentary more way out or triplice and many other required as device-free and a service-free and	Need for maintenance/spare none, sw	none, swap out or replace ancillary		n/a	n/a	n/a	n/a	n/a	n/a	n/a	none required	n/a	n/a
		device when needed		biohazard waste	biohazard waste	biohazard waste	General waste	biohazard waste	biohazard waste	biohazard waste	biohazard waste	biohazard waste	biohazard waste
		3485: 2016 compliant c	emergency use listing/authorization or WHO prequalification or other stringent regulatory authority approval	FDA EUA	FDA EUA	FDA EUA	FDA EUA	FDA EUA	FDA EUA	FDA EUA	CE	FDA EUA	CE
Mandiszturing S013485-2016 compliant grapping unduring statisticity approal.	Accessibility capabili	to maximize accessibility, all product ability to rapidly scale-up production allows borad use, including in low	n and offer the product at a cost that	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a

Table 52: Selected indirect POCT (antibody) - WHO TPP Criteria	
--	--

	Wolrd Health Or	rganization v.1.0	FDA EUA Selected Antibody POCT										FIND Selected Antibody POCT								
	Acceptable	Desirable	COVID-19 IgG/IgM Rapid Test	Wantai SARS-CoV-2 Ab Rapid Test	RightSign COVID-19 IgG/IgM Rapid Test	LYHER COVID-19 IgM/lgG Combo Test	healgen COVID-19 IgG/IgM Rapid Test	Orawell IgM/IgG Rapid Test	Rapid COVID-19 IgM/IgG Combo Test	COVID-19 IgM/IgG Antibody Detection Kit	SGTI-flex COVID-19 lgG	SARS-CoV-2 IgG/IgM Rapid Test	COVID-19 IgM/IgG Gold	AlTest COVID-19 IgG/IgM Rapid Test	COVID-19 IgM/IgG Rapid Test	Healgen COVID-19 IgM/IgG Rapid Test	COVID-19 IgM/IgG Rapid Test	Wondfo SARS-CoV-2 Ab Test	AMP Rapid SARS-CoV-2 IgM/IgG Test	SARS-CoV-2 lgM/lgG Rapid Test	NG IgG/IgM Rapid Test
Manufacturer			Assure Tech. (Hangzhou) Co. Ltd.	Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.	Hangzhou Biotest Biotech Co., Ltd.	Hangzhou Laihe Biotech Co., Ltd	Verify Diagnostics	Jangsu Well Biotech Co., Ltd.	Megra Health Inc.	Nirmidas Biotech	Sugentech, Inc.	Xamen Biotime Biotechnology Co., Ltd.	Technogenetics srl	Hangzhou Alltest Biotech Co., Ltd.	VivaChek Biotech (Hangzhou) Co., Ltd.	Verify Diagnostics	BioMedomics, Inc.	Guangzhou Wondfo Biotech Co., Ltd., China	AMEDA Labordiagnostik GmbP	MEDsan GmbH	NG Biotech Laboratoires
Country			China	China	China	China	USA	China	USA	USA	Korea	China	Italy	China	China	USA	USA	China	Austria	Germany	France
URL			http://www.damagent.can/contact.h ani	downizad	https://www.fda.gos/ineda/138867/ download	100pc//www.fds.gov/nedia/120409/ downizad, 100p//www.lyter.com/default.acpu?p ageid+118pageType=detail&id=54	https://venfydagnostics.com/healges- could 19-igg-ign-capid sett-receives- fda-eua-approxal/	http://www.fda.gov/media/142422/ download	http://www.megsaheaith.com/produ cts/Btapid-antibody-test	https://www.sinnidas.com/nimidae covid19-ignigg-antbody-detection-kit eua-authorbed	https://sugentech.com/products/prod ucto-view.php?cts?Matarget=829827	https://www.fda.gov/media/140463/ download	http://www.technogenetics.it/it/prod atti/coxid_th(rapid-tect)rapid-tect-com cox-2-ign-igg-gold	http://www.albests.com.cr/EN/Piodu ctMain.asp?cclassid-2&classid-61	https://www.vivachek.com/en/produ prod-rapidzect.tom	https://wwflydlagnostics.com/thealgen coxid-59-igg-igm-capid-terd-ecceives- fda-eux-approval/	https://www.biomedomics.com/produ cts:/infectious-disease/covid-09-tt/	http://www.bicarx.com/SAKS-Cot- INION/sbodyNIOT+stNiD(June/shNiO FlowNiD0M/sthod).pdf	https://www.amp-med.com/news- napid-text-cam-cav-2	https://www.medias.eu/en/detection /	an https://ingbiotech.com/2020/07/5k/ng- tech-igg-igm-covid-28-obtains-tool- ctartect/
Intended Use	easy to use test that can be used at		POC in patient care setting; Labs: not home use	professional use only; not home	professional use only; not home	professional use only; not home	professional use only; not home	professional use only; not home	professional use only; not home	professional use only; not home	professional use only; not home	professional use only; not home		for professionals only; not home use	for professionals only; not	for professionals only; not home use	for professionals only; not	n/a	for professionals only; not home use	for professionals only; not	for professionals only; not home use
Target Population / patient	General population involved in upper	ys; groups at high risk of exposure to		use seneral population	enteral population	use general population	general population	general population	reneral population	eneral population	use eneral population	general population		reneral population	some use eneral population	nome use reneral population	some use eneral population	eeneral population	rome use eneral population	reneral population	rome use reneral population
ter gaara / para																		Protect Paperson			
Target use setting	workers or lab techs	same as acceptable + can be performed by trained lay workers	trained lab personnel; not home use.	trained lab personnel; not home use.	trained lab personnel; not home use.	trained lab personnel; not home use.	trained lab personnel; not home use.	trained lab personnel; not home use.	trained lab personnel; not home use.	trained lab personnel; not home use.	trained lab personnel; not home use.	trained lab personnel; not home use.		trained lab personnel; not home use.	trained lab personnel; not home use.	trained lab personnel; not home use.	trained lab personnel; not home use.	n/a	trained lab personnel; not home use.	trained lab personnel; not home use.	trained lab personnel; not home use.
Target molecule	at least one isotype; other biomarkers specific to prior infection	n/a	NP, Spike	Spike	spike RBD domain	S1 spike domain	\$1 spike domain	spike RSD domain	NP	S1 & RBD domains of Spike	NP & Spike RBD	spike		n/a	n/a	51 spike domain	n/a	n/a	r/a	n/a	r/a
Analytical sensitivity / LOD	currently no standard/units to express LOD; min detectable concentration of analyte	n/a	t/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a		n/a	n/a	n/a	t/a	n/a	n/a	n/a	n/a
манувсан креотюту	detect only SARS-CoV-2 specific isotype or biomarker	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a		n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Sensitivity (PPA) Specificity (NPA)	>92%	905	100% (88.7-100) 98.8% (93.3-99.8)	100% (88.7-100) 98.8% (93.3-99.8)	100% (88.7-100)	100% (88.7-100) 98.8% (93.3-99.8)	100% (88.7-100)	100% (93.8-100) 94.8% (88.5-97.8)	100% (88.7-100)	96.6% (88.3-99.1) 97.9% (92.8-99.4)	95.7% (83.3-99.4) 100% (95.4-100)	100% (88.7-100) 96.2% (89.5-98.7)	99.2% (95.4-100) 98.3% (96.1-99.5)	98.1% (89.9-100) 100% (83.9-100)	97.30%	97% (82.8-100) 97.5% (91.3-99.7)	97% [82.8-100]	96.2% (\$7-99.5)	95.7% (90.8-98.4) 97.4% (85.2-99.9)	95.1% (83.5-99.4) 98% (89.4-100)	96.9% (93.9-98.6) 100% (92.9-100)
Specificity (NPA) Type of analysis	>97% pusitative	29925	98.8% (93.3-99.8) qualitative; lateral flow	98.8% (93.3-99.8) qualitative; lateral flow	100% (95.4-100) qualitative; lateral flow	98.8% (93.3-99.8) qualitative; lateral flow	97.5% (91.3-99.3) qualitative; lateral flow	94.8% (BLS-97.8) qualitative; lateral flow	95% (87.8-98) qualitative; lateral flow	97.9% (92.8-99.4) qualitative; lateral flow	100% (95.4-100) qualitative; lateral flow	96.2% (89.5-98.7) qualitative; lateral flow	walata (wala-aw.5)		gualitative; lateral flow	gualitative; lateral flow	97.1% (90.1-99.7) qualitative; lateral flow	100% (\$3.9-100) qualitative; lateral flow	97.4% (85.2-99.9) qualitative; lateral flow	98% (89.4-100) qualitative; lateral flow	gualitative; lateral flow
Interpretation	visual; portable automated reader	visual - device free	visual	Visual	sisual	visual	visual	visual	visual	visual	visual	sisual		visual	visual	Visual	visual	visual	disual	visual	visual
Sample type	plasma; serum;	n/a	whole blood; serum/plasma; fingerstick blood	whole blood; serum/plasma; fingerstick blood	whole blood; serum/plasma	serum/plasma		whole blood; setum/plasma; not fingerstick blood	serum/plasma	secum/plasma	venous blood, serum, plasma (not figeratick)	venous blood, serum, plasma (not figeratick)		whole blood (fingertip/venous), serum, plasma	whole blood (fingertip/venous), serum, plasma	, whole blood; serum/plasma; not fingerstick blood	whole blood (capilary, venous), serum, plasma	whole blood/serum/plasma	whole blood/serum/plasma	whole blood (fingerstick), serum, plasma	whole blood (fingenstick), serum, plasma
Test kit format	collection	same plus controls	intenal control; pos/neg control not included	intenal control; pos/neg control not included	intenal control; pos/neg control not included	interal control; pos/neg control not included	intenal control; pos/neg control not included	not included	not included	not included	not included	intenal control; pos/neg control not included		intenal control; pos/neg control not included	n/a	not included	intenal control; pos/neg control not included	19.2	n/a	interal control; pos/neg control not included	ol intenal control; pos/neg control not included
End use profile	Health care facility worker		trained lab personnel	trained lab personnel	trained lab personnel	trained lab personnel	trained lab personnel	trained lab personnel	trained lab personnel	trained lab personnel	trained lab personnel	trained lab personnel		trained lab personnel	trained lab personnel	trained lab personnel	trained lab personnel	trained lab personnel	trained lab personnel	trained lab personnel	trained lab personnel
Training needs	c0.5 days	<2hr (quick reference)	t/a	n/a	r/a	n/a 1 (separate plasma/serum)	t/a	n/a	r/a 1 (separate plasma/secum)	n/a	n/a	r/a			n/a	n/a	t/a	n/a	t/a	n/a	e/a
Sample preparation steps Reasents reconstitution	I very simple to do	to, ready to use	ready to use	ready to use	ready to use	1 (separate plasma/serum) ready to use	ready to use	ready to use	1 (separate plasma/serum) ready to use	a (separate plasma/serum) ready to use	ready to use	ready to use		ready to use	ready to use	ready to use	ready to use	n/a	ready to use	ready to use	o ready to use
Need to transfer a precise volume			reary to use	ready to use		easy is use					ready or use							10.2	1Dul whole blood, Sul		ready to use
of sample Number of timed steps	if autofill or volume marking	no or a few drops	filline .	104	fill line (10ul)	10ul	fill line (Sul)	fill line (10ul)	fill line (10ul)	fill line (10ul)	104	one drop (10-15ul)		10ul (fill line)	20ul (fill line)	fill line (Sul)	15ul blood; 10ul serum/plasma	n/a	serum/plauma	10ul (fill line)	tr/a
Time to result	c40min	4 <20min	15min	15min	10min	10min	10min	10min	10min	10min	10min	20min		10min	15min	10min	10min	15min	10min	10min	15min
Sample stability pre-testing		3hr RT (50-35oC); 24hr (2-8oC)	whole blood 3 days at 2-8oC; servan/plasma 7 days 2-8oC	serum/plasma 7 day 2-8oC or 3 wis -15oC; whole blood used immediately	serum/plasma 3 days at 2-8oC; - 2DoC for longer-term; whole blood 2 days at 2-8oC; do not freeze blood	2-BoC for 2 days; <-20oC long- term		serum/plasma 2-8oC for 5 days; -70oC for longterm;	serum/plasma <3 days at 2- BoC; -20oC for <3ms; -70oC longterm;	4-8oC <3 days; -20oC <1 mo;	2-BoC <5 days; -70oC longterm;	serum/plasma <14 days at 2- BoC; -20oC for <3mo; whole blood 2-BoC <3 days;		serum/plasma 7 days at 2-8oC; 2DoC for long-term; whole blood 2 days at 2-8oC; do not freeze blood	n/a	serum/plasma 3 days at 2-BoC; 20oC for Imo; whole blood 2 days at 2-BoC; do not freeze blood	anticoagulated blood 2-8oC for 5 days serum/plasma 208oC 5 days or -20oC longterm;	n/a	n/a	serum/plasma 3 days at 2-8oC; 20oC for longterm; whole bloos 2 days at 2-8oC; do not freeze blood	
Result validity stability	fixed reading time eSS invalid results with correct use	stored images or 6 weeks	30min	20min	20min	15min	15min	15min	20min	15min	20min	20min		20min	20min	15min	15min	n/a	15min	15min	e/a
Invalid rate Operating conditions		<1% invalid results with correct use 10-40eC: 25-90% RH: altitude 3000m	1/a	r/a room temperature	r/a room temperature	n/a room temperature	r/a room temperature	n/a room temperature	n/a room temperature	n/a room temperature	n/a room temperature	r/a room temperature		r/a room temperature	n/a room temperature	r/a room temperature	t/a toom temperature	n/a room temperature	r/a room temperature	n/a room temperature	r/a room temperature
Test kit stability and storage		18-24mo, 2-40oC, 92% RH	2-30oC	2-30oC for 9mo	2-30oC	2-30oC. dark				4-25cC	2-8cC	Smo at RT: 9mo at 2-8oC		2-30oC	2-30oC	2-30oC:	2-30oC	2-30oC:	2-30eC	2-300C:	2-30oC:
Stability of kit once opened	2hr	4br	2hr	0.5hr	lhr	0.5hr	1hr	2-BoC <7 days	use immediately	15min	30 days at 2-BoC	use immediately		t/a	t/a	lhr	1hr	n/a	t/a	n/a	t/a
Specimen capacity & throughput		>10/hr per operator	1/a	n/a	t/s	o/a	t/a	n/a	n/a	5/a	n/a	r/a		t/a	5/a	n/a	1/a	n/a	t/a	n/a	t/a
Safety precautions	standard blood collection safety precautions	ty'a	standard	standard	standard	standard	standard	standard	standard	standard	standard	standard		standard	standard	standard	standard	n/a	standard	standard	e/a
Quality control	internal control (sample flow/migration); positive / negative controls sold separately	internal control; lyophilized positive/negative conrols provided	internal control; positive, negative controls optional	internal control; positive, negative controls optional	internal control; positive, negative controls optional	Internal control; positive, negative controls optional		internal control; positive, negative controls optional	internal control; positive, negative controls optional	internal control; positive, negative controls optional	internal control; positive, negative controls optional	Internal control; positive, negative controls optional		n/a	n/a	internal control; positive, negative controls optional	internal control; positive, negative controls optional	n/a	internal control; positive, negative controls optional	internal control; positive, negative controls optional	n/a
Remote connectivity capacity	device-based: remote export of data possible; no device: export through separate 3rd party reader	test is compatible with readers and other data capture devices	10	no	no	no	no	no	no	no	no	no		no	no	no	no	n/a	ey'a	n/a	n/a
Need for additional equipment	handheld: <1kg; battery or solar power; >6hr rechargable battery life	no additional equipment	no	no	10	no	ro	10	no	10	no	no		10	10	no	no	n/a	n/a	n/a	n/a
Need for maintenance/spare parts		none required as device free	10	no	10	no	no	10	10	00	no	no		10	10	no	10	n/a	n/a	n/a	n/a
Waste/disposal requirements	standard biohazardous waste disposal	recyclable or compostable plastic	biohazard waste	biohazard waste	biohazard waste	biohazard waste	biohazard waste	biohazard waste	biohazard waste	biohazard waste	biohazard waste	biohazard waste		biohazard waste	biohazard waste	biohazard waste	biohazard waste	n/a	biohazard waste	biohazard waste	e/a
Accessibility	to maximize accessibility, all produ capability to rapidly scale-up productio allows broad use, including in low	on and offer the product at a cost that	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a		n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a